Effects of tea Catechins on inflammation-related cardiovascular diseases

Current Immunology Reviews

Volumn 5, Issue 2, 2009, Pages 167-174

  Suzuki, Jun Ichi ^a   Isobe, Mitsuaki ^b   Morishita, Ryuichi ^c   Nagai, Ryozo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Catechin; Inflammation; Nuclear factor kappa B; Tea

Indexed keywords

CATECHIN; CD11B ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSCRIPTION FACTOR AP 1; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CELL ADHESION; CELL INFILTRATION; CYTOKINE RELEASE; ENZYME INHIBITION; ENZYME REGULATION; GRAFT REJECTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART TRANSPLANTATION; HEART VENTRICLE REMODELING; HUMAN; INFLAMMATION; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TEA;

EID: 68549085525     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339509788167001     Document Type: Review

References (70)

1. Mukamal KJ, Maclure M, Muller JE, Sherwood JB, Mittleman MA. Tea consumption and mortality after acute myocardial infarction. Circulation 2002; 105: 2476-2481.
2. Arts ICW, Peter Hollman PCH, Feskens EJM, de Mesquita HBB, Kromhout D. Catechin intake might explain the inverse relation between tea consumption and ischemic heart disease: the Zutphen Elderly Study. Am J Clin Nutr 2001; 74: 227-32.
3. Kuriyama S, Shimazu T, Ohmori K, et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA 2006; 296: 1255-65.
4. Shimazu T, Kuriyama S, Hozawa A, et al. Dietary patterns and cardiovascular disease mortality in Japan: a prospective cohort study. Int J Epidemiol 2007; 36: 600-9.
5. Kuriyama S. The relation between green tea consumption and cardiovascular disease as evidenced by epidemiological studies. J Nutr 2008; 138: 1548S-53S
6. Ishikawa T, Suzukawa M, Ito T, et al. Effect of tea flavonoid supplementation on the susceptibility of low-density lipoprotein to oxidative modification. Am J Clin Nutr 1997; 66: 261-6.
7. Junkun J, Selman SH, Swiercz R, Skrzypczak-Jankun E. Why drinking tea could prevent cancer. Nature 1997; 387: 561.
8. Beecher GR, Warden BA, Merken H. Analysis of tea polyphenols. Proc Soc Exp Biol Med 1999; 220: 267-70.
9. Yang CS, Landau JM, Huang MT, Newmark HL. Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu Rev Nutr 2001; 21: 381-406.
10. Lin YL, Lin JK. (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappaB. Mol Pharmacol 1997; 52: 465-72.
11. Benelli R, Vene R, Bisacchi D, Garbisa S, Albini A. Anti-invasive effects of green tea polyphenol epigallocatechin-3-gallate (EGCG), a natural inhibitor of metallo and serine proteases. Biol Chem 2002; 383: 101-5.
12. Suzuki J, Ogawa M, Maejima Y, et al. Tea catechins attenuate chronic ventricular remodeling after myocardial ischemia in rats. J Mol Cell Cardiol 2007; 42: 432-40.
13. Suzuki J, Ogawa M, Futamatsu H, Kosuge H, Sagesaka YM, Isobe M. Tea catechins improve left ventricular dysfunction, suppress myocardial inflammation, fibrosis, and alter cytokine expression in rat autoimmune myocarditis. Eur J Heart Fail 2007; 9: 152-9.
14. Suzuki J, Ogawa M, Sagesaka YM, Isobe M. Tea catechins attenuate ventricular remodeling and graft arterial diseases in murine cardiac allografts. Cardiovasc Res 2006; 69: 272-9.
15. Morishita R, Sugimoto T, Aoki M, et al. In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 1997; 3: 894-9.
16. Li C, Browder W, Kao RL. Early activation of transcription factor NF-κB during ischemia in perfused rat heart. Am J Physiol 1999; 45: H543-H52.
17. Li Q, Verma IM, NF-κB regulation in the immune system. Nat Rev Immunol 2002; 2: 725-34.
18. Chandrasekar B, Freeman GL. Induction of nuclear factor B and activation protein 1 in postischemic myocardium. FEBS Lett 1997; 401: 30-4.
19. Onai Y, Suzuki J, Kakuta T, et al. Inhibition of IkB phosphorylation in cardiomyocytes attenuates myocardial ischemia/ reperfusion injury. Cardiovasc Res 2004; 63: 51-9.
20. Cheng XW, Kuzuya M, Nakamura K, et al. Mechanisms of the inhibitory effect of epigallocatechin-3-gallate on cultured human vascular smooth muscle cell invasion. Arterioscler Thromb Vasc Biol 2005; 25: 1864-70.
21. Ivanov V, Roomi MW, Kalinovsky T, Niedzwiecki A, Rath M. Anti-atherogenic effects of a mixture of ascorbic acid, lysine, proline, arginine, cysteine, and green tea phenolics in human aortic smooth muscle cells. J Cardiovasc Pharmacol 2007; 49: 140-5.
22. El Bedoui J, Oak MH, Anglard P, Schini-Kerth VB. Catechins prevent vascular smooth muscle cell invasion by inhibiting MT1-MMP activity and MMP-2 expression. Cardiovasc Res 2005; 67: 317-25.
23. Kim CH, Moon SK. Epigallocatechin-3-gallate causes the p21/WAF1-mediated G(1)-phase arrest of cell cycle and inhibits matrix metalloproteinase-9 expression in TNF-alpha-induced vascular smooth muscle cells. Arch Biochem Biophys 2005; 435: 264-72.
24. Maeda K, Kuzuya M, Cheng XW, et al. Green tea catechins inhibit the cultured smooth muscle cell invasion through the basement barrier. Atherosclerosis 2003; 166: 23-30.
25. Singh AK, Seth P, Anthony P, Husain MM, et al. Green tea constituent epigallocatechin-3-gallate inhibits angiogenic differentiation of human endothelial cells. Arch Biochem Biophys 2002; 401: 29-37.
26. Yamazaki KG, Romero-Perez D, Barraza-Hidalgo M, et al. Short-and long-term effects of (-)-epicatechin on myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2008; 295: H761-7.
27. Ho YC, Yang SF, Peng CY, Chou MY, Chang YC. Epigallocatechin-3-gallate inhibits the invasion of human oral cancer cells and decreases the productions of matrix metalloproteinases and urokinase-plasminogen activator. 2007; 36: 588-93.
28. Zhen MC, Wang Q, Huang XH, et al. Green tea polyphenol epigallocatechin-3-gallate inhibits oxidative damage and preventive effects on carbon tetrachloride-induced hepatic fibrosis. J Nutr Biochem 2007; 18: 795-805.
29. Lee JH, Chung JH, Cho KH. The effects of epigallocatechin-3-gallate on extracellular matrix metabolism. J Dermatol Sci 2005; 40: 195-204.
30. Haas GJ. Etiology, evaluation, and management of acute myocarditis. Cardiol Rev 2001; 9: 88-95.
31. Oakley CM. Myocarditis, pericarditis and other pericardial diseases. Heart 2000; 84: 449-54.
32. Batra AS, Lewis AB. Acute myocarditis. Curr Opin Pediatr 2001; 13: 234-9.
33. Zee-Cheng CS, Tsai CC, Palmer DC, Codd JE, Pennington DG, Williams GA. High incidence of myocarditis by endomyocardial biopsy in patients with idiopathic congestive cardiomyopathy. J Am Coll Cardiol 1984; 3: 63-70.
34. Parrillo JE, Aretz HT, Palacios I, Fallon JT, Block PC. The results of transvenous endomyocardial biopsy can frequently be used to diagnose myocardial diseases in patients with idiopathic heart failure: endomyocardial biopsies in 100 consecutive patients revealed a substantial incidence of myocarditis. Circulation 1984; 69: 93-101.
35. Kodama M, Matsumoto Y, Fujiwara M, Masani F, Izumi T, Shibata A. A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol 1990; 57: 250-62.
36. Kodama M, Izumi T. Experimental autoimmune myocarditis. Acta Med Bio 1991; 39: 1-10.
37. Kitabayashi H, Isobe M, Watanabe N, Suzuki J, Yazaki Y, Sekiguchi M. FTY 720 prevents development of experimental autoimmune myocarditis through reduction of circulating lymphocytes. J Cardiovasc Pharmacol 2000; 35: 410-6.
38. Yokoseki O, Suzuki J, Kitabayashi H, et al. cis element decoy against nuclear factor-κB attenuates development of experimental autoimmune myocarditis in rats. Circ Res 2001; 89: 899-906.
39. Futamatsu H, Suzuki J, Kosuge H, et al. Attenuation of experimental autoimmune myocarditis by blocking activated T cells through inducible costimulatory molecule pathway. Cardiovasc Res 2003; 59: 95-104.
40. Ahn HY, Xu Y, Davidge ST. Epigallocatechin-3-O-gallate inhibits TNFalpha-induced monocyte chemotactic protein-1 production from vascular endothelial cells. Life Sci 2008; 82: 964-8.
41. Guruvayoorappan C, Kuttan G. (+)-Catechin inhibits tumour angiogenesis and regulates the production of nitric oxide and TNF-alpha in LPS-stimulated macrophages. Innate Immun 2008; 14: 160-74.
42. Ahmed S, Marotte H, Kwan K, et al. Epigallocatechin-3-gallate inhibits IL-6 synthesis and suppresses transsignaling by enhancing soluble gp130 production. Proc Natl Acad Sci USA 2008; 105: 14692-7.
43. Crouvezier S, Powell B, Keir D, Yaqoob P. The effects of phenolic components of tea on the production of pro- and anti-inflammatory cytokines by human leukocytes in vitro. Cytokine 2001; 13: 280-6.
44. Abboud PA, Hake PW, Burroughs TJ, et al. Therapeutic effect of epigallocatechin-3-gallate in a mouse model of colitis. Eur J Pharmacol 2008; 579: 411-7.
45. Taylor DO, Edwards LB, Boucek MM, Trulock EP, Keck BM, Hertz MI. The registry of the International Society for Heart and Lung Transplantation: twenty-first official adult heart transplant report - 2004. J Heart Lung Transplant 2004; 23: 796-803.
46. Pinney SP, Mancini D. Cardiac allograft vasculopathy: advances in understanding its pathophysiology, prevention, and treatment. Curr Opin Cardiol 2004; 19: 170-6.
47. Suzuki J, Isobe M, Aikawa M, et al. Nonmuscle and smooth muscle myosin heavy chain expression in rejected cardiac allograft. A study in rat and monkey models. Circulation 1996; 96: 1118-24.
48. Hosenpud JD. Immune mechanism of cardiac allograft vasculopathy: an update. Transplant Immunol 1993; 1237-49.
49. Suzuki J, Cole SE, Batirel S, et al. Tumor necrosis factor receptor - 1 and -2 double deficiency reduces graft arterial disease in murine cardiac allografts. Am J Transplant 2003; 3: 968-976.
50. Isobe M, Yagita H, Okumura K, Ihara A. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 1992; 255: 1125-7.
51. Kosuge H, Suzuki J, Gotoh R, et al. The induction of immunological tolerance to cardiac allograft by simultaneous blockade of inducible co-stimulator (ICOS) and CTLA4 pathway. Transplantation 2003; 75: 1374-9.
52. Kosuge H, Suzuki J, Kakuta T, et al. Attenuation of graft arterial disease by manipulation of the LIGHT pathway. Arterioscler Thromb Vasc Biol 2004; 24: 1409-1415.
53. Koga N, Suzuki J, Kosuge H, et al. The blockade of the interaction between PD-1 and PD-L1 accelerates graft arterial disease in cardiac allografts. Arterioscler Thromb Vasc Biol 2004; 24: 2057-62.
54. Ludwig A, Lorenz M, Grimbo N, et al. The tea flavonoid epigallocatechin-3-gallate reduces cytokine-induced VCAM-1 expression and monocyte adhesion to endothelial cells. Biochem Biophys Res Commun 2004; 316: 659-65.
55. Chae YJ, Kim CH, Ha TS, Hescheler J, Ahn HY, Sachinidis A. Epigallocatechin-3-O-gallate inhibits the angiotensin II-induced adhesion molecule expression in human umbilical vein endothelial cell via inhibition of MAPK pathways. Cell Physiol Biochem 2007; 20: 859-66.
56. Handa O, Naito Y, Takagi T, et al. Inhibitory effects of catechins on neutrophil-dependent gastric inflammation. Redox Rep 2002; 7: 324-8.
57. Chen WC, Hayakawa S, Shimizu K, Chien CT, Lai MK. Catechins prevents substance P-induced hyperactive bladder in rats via the downregulation of ICAM and ROS. Neurosci Lett 2004; 367: 213-7.
58. Suzuki J, Ogawa M, Izawa A, Sagesaka YM, Isobe M. Dietary consumption of green tea catechins attenuate hyperlipidemia-induced atherosclerosis and systemic organ damage in mice. Acta Cardiologica 2005; 60: 271-6.
59. Suzuki J, Morishita R, Amano J, Kaneda Y, Issobe M. Decoy against nuclear factor-kappa B attenuates myocardial cell infiltration and arterial neointimal formation in murine cardiac allografts. Gene Ther 2000; 7: 1847-52.
60. Wakatsuki S, Suzuki J, Ogawa M, et al. A novel IKK inhibitor suppresses heart failure and chronic remodeling after myocardial ischemia via MMP alteration. Expert Opin Ther Targets 2008; 12: 1469-76.
61. Onai Y, Suzuki J, Maejima Y, et al. Inhibition of NF-κB improves left ventricular remodeling and cardiac dysfunction after myocardial infarction. Am J Physiol Heart Circ Physiol 2007; 291: H530-8.
62. Aneja R, Hake PW, Burroughs TJ, Denenberg AG, Wong HR, Zingarelli B. Epigallocatechin, a green tea polyphenol, attenuates myocardial ischemia reperfusion injury in rats. Mol Med 2004; 10: 55-62.
63. Han DW, Lim HR, Baek HS, et al. Inhibitory effects of epigallocatechin-3-O-gallate on serum-stimulated rat aortic smooth muscle cells via nuclear factor-kappaB down-modulation. Biochem Biophys Res Commun 2006; 345: 148-55.
64. Kim SJ, Jeong HJ, Lee KM, et al. Epigallocatechin-3-gallate suppresses NF-kappaB activation and phosphorylation of p38 MAPK and JNK in human astrocytoma U373MG cells. J Nutr Biochem 2007; 18: 587-96.
65. Mackenzie GG, Oteiza PI. Modulation of transcription factor NF-kappaB in Hodgkin's lymphoma cell lines: effect of (-)-epicatechin. Free Radic Res 2006; 40: 1086-94.
66. Babu PV, Liu D. Green tea catechins and cardiovascular health: an update. Curr Med Chem 2008; 15: 1840-50.
67. Wolfram S. Effects of green tea and EGCG on cardiovascular and metabolic health. J Am Coll Nutr 2007; 26: 373S-388S.
68. Shenouda SM, Vita JA. Effects of flavonoid-containing beverages and EGCG on endothelial function. J Am Coll Nutr 2007; 26: 366S-372S.
69. Basu A, Lucas EA. Mechanisms and effects of green tea on cardiovascular health. Nutr Rev 2007; 65: 361-75.
70. Cabrera C, Artacho R, Giménez R. Beneficial effects of green tea - a review. J Am Coll Nutr 2006; 25: 79-99.